Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Launched by M.D. ANDERSON CANCER CENTER · Jun 19, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on gathering important information about patients who have low-grade ovarian or peritoneal tumors. These tumors are types of cancer that grow slowly and may not behave as aggressively as other cancers. By collecting data about the kinds of tumors, the treatments patients receive, and their follow-up care, researchers hope to learn more about these cancer types and eventually develop better treatments for them.
To be eligible for this study, participants should be female patients who have had their low-grade tumors change into a higher-grade carcinoma since their initial diagnosis. This includes specific types of ovarian and peritoneal tumors. If you choose to participate, you'll help researchers by providing valuable information that can lead to advancements in understanding and treating these conditions. The study is currently recruiting participants, so there is an opportunity to contribute to this important research.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- * Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis:
- • Ovarian tumor of low malignant potential
- • Low-grade serous carcinoma of the ovary
- • Primary peritoneal tumor of low malignant potential
- • Low-grade serous carcinoma of the peritoneum
- • Psammocarcinoma
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
David M Gershenson
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials